Sonnet BioTherapeutics Holdings (SONN)

Sonnet BioTherapeutics Holdings (SONN) Stock Price & Analysis


SONN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.21 - $4.55
Previous Close$0.5
Average Volume (3M)2.95M
Market Cap
Enterprise Value-$999.40K
Total Cash (Recent Filing)$11.40M
Total Debt (Recent Filing)$237.61K
Price to Earnings (P/E)-0.1
May 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.62
Shares Outstanding27,478,686
10 Day Avg. Volume9,811,872
30 Day Avg. Volume2,952,031
Standard Deviation0.29
Financial Highlights & Ratios
Price to Book (P/B)38.16
Price to Sales (P/S)378.72
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-5.03
Enterprise Value/Gross Profit-2.86
Enterprise Value/Ebitda0.07
Price Target Upside1960.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Sonnet BioTherapeutics Holdings’s price range in the past 12 months?
Sonnet BioTherapeutics Holdings lowest stock price was $0.20 and its highest was $4.55 in the past 12 months.
    What is Sonnet BioTherapeutics Holdings’s market cap?
    Currently, no data Available
    When is Sonnet BioTherapeutics Holdings’s upcoming earnings report date?
    Sonnet BioTherapeutics Holdings’s upcoming earnings report date is May 10, 2023 which is 25 days ago.
      How were Sonnet BioTherapeutics Holdings’s earnings last quarter?
      Sonnet BioTherapeutics Holdings released its earnings results on Feb 13, 2023. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.1 by $0.3.
        Is Sonnet BioTherapeutics Holdings overvalued?
        According to Wall Street analysts Sonnet BioTherapeutics Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Sonnet BioTherapeutics Holdings pay dividends?
          Sonnet BioTherapeutics Holdings does not currently pay dividends.
          What is Sonnet BioTherapeutics Holdings’s EPS estimate?
          Sonnet BioTherapeutics Holdings’s EPS estimate is -$0.5.
            How many shares outstanding does Sonnet BioTherapeutics Holdings have?
            Sonnet BioTherapeutics Holdings has 20,232,904 shares outstanding.
              What happened to Sonnet BioTherapeutics Holdings’s price movement after its last earnings report?
              Sonnet BioTherapeutics Holdings reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.1. Following the earnings report the stock price went down -4.167%.
                Which hedge fund is a major shareholder of Sonnet BioTherapeutics Holdings?
                Currently, no hedge funds are holding shares in SONN


                Sonnet BioTherapeutics Holdings Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Sonnet BioTherapeutics Holdings

                Sonnet BioTherapeutics (NASDAQ:SONN) is a clinical-stage biotechnology company that is focused on the development of drugs for the treatment of cancer.


                Top 5 ETFs holding SONN

                Market Value
                Smart Score
                iShares Core S&P Total U.S. Stock Market ETF
                Up to five ETFs with an Outperform Smart Score that hold SONN. The ETFs are listed according to market value of SONN within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Actinium Pharmaceuticals
                Oncolytics Biotech

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis